Validation of the INNO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment.
about
Multiplex fluorescence melting curve analysis for mutation detection with dual-labeled, self-quenched probes.High-throughput matrix-assisted laser desorption ionization-time of flight mass spectrometry as an alternative approach to monitoring drug resistance of hepatitis B virus.Hepatitis B virus compartmentalization in the cerebrospinal fluid of HIV-infected patientsDe novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine.Dynamics of Genotypic Mutations of the Hepatitis B Virus Associated With Long-Term Entecavir Treatment Determined With Ultradeep Pyrosequencing: A Retrospective Observational StudyCombined Analysis of the Prevalence of Drug-Resistant Hepatitis B Virus in Antiviral Therapy-Experienced Patients in Europe (CAPRE).Implementation of Next-Generation Sequencing for Hepatitis B Virus Resistance Testing and Genotyping in a Clinical Microbiology Laboratory.Application of coamplification at lower denaturation temperature-PCR sequencing for early detection of antiviral drug resistance mutations of hepatitis B virus.Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations.Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing.Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection.
P2860
Q33892578-93A129F9-3111-4143-8A41-86466F922B5BQ34997985-A4A00C52-57C2-444F-BFF6-E73F2F214A35Q35582552-FE8621B2-B919-419B-82D0-9ED01BC50AE1Q36800501-4E6A4096-ABD1-4C3C-B818-4C6222EF1BCFQ37624126-C2EDC8C0-043A-4BF8-B297-122B274E3153Q38424625-69EF1EBD-781A-4FBA-9B7C-B1FD6A1AA17BQ40355667-D0742384-730C-4A75-9A37-0D788EAC4D27Q42210924-DC5258D6-7644-4535-86BA-B59A462BF6EDQ42237251-BD075FD3-78E1-4D76-9F30-5A4A233DF22BQ44675493-A35C6CE3-0E5F-41BE-9324-9B97A150C4FDQ46044243-0737C464-DB45-453E-A6B3-5A1E596F7B99
P2860
Validation of the INNO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Validation of the INNO-LiPA HB ...... g nucleoside analog treatment.
@en
Validation of the INNO-LiPA HBV DR assay
@nl
type
label
Validation of the INNO-LiPA HB ...... g nucleoside analog treatment.
@en
Validation of the INNO-LiPA HBV DR assay
@nl
prefLabel
Validation of the INNO-LiPA HB ...... g nucleoside analog treatment.
@en
Validation of the INNO-LiPA HBV DR assay
@nl
P2093
P2860
P356
P1476
Validation of the INNO-LiPA HB ...... ng nucleoside analog treatment
@en
P2093
J Doutreloigne
N D'Heuvaert
P2860
P304
P356
10.1128/AAC.00970-09
P407
P577
2010-01-11T00:00:00Z